- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04574531
us Elastography and us Doppler in Differentiating Breast Masses
Comparative Study of US Elastography and Color Doppler US in Differentiating Breast Masses in Correlation to Histopathology
Study Overview
Status
Conditions
Detailed Description
Breast cancer is the most fre¬quently diagnosed cancer and the chief cause of cancer death among women worldwide, with an es¬timated 1.7 million cases.
Breast cancer alone accounts for 25% of all cancer cases and 15% of all cancer deaths among females .so, Its high incidence has led to research on new diagnostic imaging techniques for early diagnosis and to improve patient's mortality rate[1].
Application of imaging techniques together with other investigation would help clinical decision making. the most important factor in reducing mortality of certain cancers is an early diagnosis of cancer via screening based on imaging[2].
US is an accurate method for detection of breast masses ; however, US has a low accuracy in differentiating between benign from malignant breast masses . US could suggest a malignancy likelihood criteria of a breast mass, such as hypoechogenicity, irregular margins, microcalcifications, increased vascularity by Doppler and us elastography [3].
Ultrasound elastography provides a non-invasive evaluation of the "stiffness" of a lesion. Recent studies show that ultrasonographic elastogra¬phy (USE) provides higher diagnostic accuracy together with Doppler application compared with conventional B-mode ultrasonography during breast cancer diagnosis, which eventually helps to reduce false-positive results (ie, increased specificity) and therefore is useful in avoiding breast biopsy[4].
US elastography has been used to detect the nature of breast lesions , by measuring the tissue stiffness non invasively. It depends on tissue deformation strain that is caused by external compression. it is complementary to gray scale findings particularly in lesions with indeterminate US findings, also US elastography could be used to guide the follow up of leisons diagnosed as benign at ( FNA) fine needle aspiration.[5][6]
Study Type
Enrollment (Anticipated)
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All patients will subjected to :
Full history taking, clinical examination by referring physician . Then the patient will be examined by Gray scale US , doppler and elastography at Radiology department.
On Gray scale:Echogenicity of the mass with respect to normal breast parenchyma, diameter A/T ,margins and calcifications.
While on Color Doppler, to describe the vascular patterns. Masses and axillary lymph nodes (if detected) will be identified as nonvascular or vascular (peripheral, central, or mix).
(A) Strain elastography Color coding is classified into 5 groups according to the Ueno classification, score one (softest component) and score five (hardest component) .
(B) Shear wave elastography A ROI rectangular box was adjusted on the observed target lesion including sufficient amount of surrounding healthy breast tissue.
Description
Inclusion Criteria:
- patients with breast masses referred to our department of diagnostic radiology for radiological assessment.
Exclusion Criteria:
Patients with purely cystic lesions on conventional breast ultrasound. Breast implant. Superficial lesions (>5 mm deep to skin surface).
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
comparison between us elastography and doppler us of breast masses with the histopathology of the specimens
Time Frame: baseline
|
comparitive study between us elastography and doppler us of breast masses in differentiating breast masses
|
baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Sigrist RMS, Liau J, Kaffas AE, Chammas MC, Willmann JK. Ultrasound Elastography: Review of Techniques and Clinical Applications. Theranostics. 2017 Mar 7;7(5):1303-1329. doi: 10.7150/thno.18650. eCollection 2017.
- Barr RG. Breast Elastography: How to Perform and Integrate Into a "Best-Practice" Patient Treatment Algorithm. J Ultrasound Med. 2020 Jan;39(1):7-17. doi: 10.1002/jum.15137. Epub 2019 Oct 16.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- breast US elastography
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Lump (Malignant)
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
Services Hospital, LahoreCompletedBreast Lump in Females Presenting to Surgical OPD
-
Franciscus Gasthuis & Vlietland (Hospital)RecruitingMalignant Breast Tumours | Benign Breast LesionsNetherlands
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); AmgenActive, not recruitingEdema | Erythema | Breast Carcinoma | Invasive Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Inflammatory Breast Carcinoma | Breast Lump | Peau d'OrangeUnited States
-
Massachusetts General HospitalNational Institutes of Health (NIH)Enrolling by invitationMalignant Neoplasm of Breast | Breast Benign | Breast Malignant TumorUnited States
-
National Cancer Institute, ThailandCompleted
-
National Cancer Institute, ThailandCompleted
-
National Cancer Institute (NCI)SuspendedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast CarcinomaUnited States
-
Seoul National University HospitalCompletedHormone Receptor Positive Malignant Neoplasm of BreastKorea, Republic of
-
Organisation for Oncology and Translational ResearchUnknownHormone Receptor Positive Malignant Neoplasm of BreastChina